Menu
Recruiting NCT06513208

Ketorolac Effects on Post-operative Pain and Lumbar Fusion

Phase IV Interventional Lumbar Spinal Fusion

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Ketorolac Tromethamine, Placebo.
Who it may be relevant to
Registry conditions: Lumbar Spinal Fusion. Basic parameters: 18 years — 85 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Ketorolac Effects on Post-operative Pain and Lumbar Fusion: a Double Blind Randomized Controlled Trial

Overview

A double blind prospective randomized trial of IV ketorolac vs. placebo in management of patients undergoing lumbar one or two level spinal fusions.

Interventions

  • Drug Ketorolac Tromethamine
    IV Ketorolac 15mg every 6 hours, x 4 doses
  • Drug Placebo
    IV saline as placebo

Primary outcome measures

  • Ketorolac results in decreased post-op opioid use when administered in the first 48 hours (measured by calculating the total amount of MME utilized during the patient's inpatient stay and comparing the control and experimental groups). [Time frame: 12 months]
Secondary outcome measures (2)
  • Ketorolac use does not decrease spinal fusion rates in one or two level fusion (failure defined as by > than 2 degrees motion on standardized flexion/extension x-rays compared to pre-op imaging analyzed by SpineCAMP software at 6 and 12 months post-op). [Time frame: 12 months]
  • Ketorolac use decreases average length of hospital stay (length of stay for both the control group and the experimental group will be counted, and a statistical average for each group will be calculated and compared). [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

  • 18-85 years old (inclusive)
  • Elective posterior lumbar instrumented fusion
  • One or two level fusion
  • Consent to participate in study and willing to adhere to study follow up
  • English proficiency

Exclusion criteria

  • < 18 or > 85 years old
  • History of renal failure, dialysis, or creatinine over 1.50 mg/dl
  • Active or recent smoker (active within past 6 months)
  • Revision surgery
  • Auto/worker compensation
  • Active cancer or history of chemotherapy in past 6 months
  • Active narcotic use within 3 months of surgery date
  • Infection at operative levels
  • Any allergies to NSAIDs or Opioids

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • University of Maryland St. Joseph Medical Center — Towson

Identifiers

NCT: NCT06513208 · HP-00109853

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗